Lynne Elizabeth Wagoner

Title: Lynne Elizabeth Wagoner: Innovator in Cardiac Therapeutics

Introduction

Lynne Elizabeth Wagoner is a prominent inventor based in Cincinnati, OH. She has made significant contributions to the field of cardiac therapeutics through her innovative research and patent work. Her expertise lies in understanding the genetic factors that influence the efficacy of beta blocker therapies.

Latest Patents

Wagoner holds a patent titled "Methods for predicting relative efficacy of a beta blocker therapy based on a B1-adrenergic receptor polymorphism." This patent outlines methods and compositions for the detection, diagnosis, and prevention of cardiac conditions. It highlights the importance of polymorphisms of the β-adrenergic receptor, particularly the Gly389 variant, which is less responsive to treatments with beta blockers such as carvedilol, metoprolol, or bisoprol. The patent emphasizes the utility of genotyping β-adrenergic receptor polymorphisms in predicting treatment responsiveness and assessing the risk of developing cardiovascular diseases.

Career Highlights

Wagoner is affiliated with the University of Cincinnati, where she conducts her research and contributes to advancements in cardiac health. Her work has implications for improving patient outcomes in heart failure and other cardiovascular conditions.

Collaborations

Wagoner collaborates with Stephen Bryant Liggett, a fellow researcher, to further explore the genetic underpinnings of cardiac conditions and enhance therapeutic strategies.

Conclusion

Lynne Elizabeth Wagoner's innovative work in the field of cardiac therapeutics exemplifies the impact of genetic research on treatment efficacy. Her contributions are paving the way for more personalized approaches to managing cardiovascular diseases.